Acute Myelogenous Leukemia Clinical Trial
Official title:
Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine and Low-dose Cytarabine for the Treatment of AML Patients Age Greater Than or Equal to 60 Years
Verified date | April 2014 |
Source | PETHEMA Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ministry of Health |
Study type | Interventional |
Primary outcome measure:
Evaluate the efficacy in terms of complete responses of induction therapy and first-line
consolidation of Clofarabine and low-dose Cytarabine with AML patients aged 60 years or
more. The first efficacy objective is evaluate the overall remission rate (TRG), where
general reference (RG) is defined as a patient who achieved complete remission (CR) or
complete remission with inadequate platelet recovery (CPR).
Secondary outcome measures:
- To evaluate disease-free survival (DFS)
- Evaluate the overall survival (OS)
- To evaluate the safety and tolerability of clofarabine and duration, severity and
relationship of adverse events (AEs) occurring during treatment
- To assess the rate of mortality at 30 days (ie, the incidence of deaths occurring
between Day 1 and Day 30 of induction cycle)
- The incidence, intensity (according to the latest version of the CTCAE classification),
duration, causality, severity and type of AA
Status | Terminated |
Enrollment | 75 |
Est. completion date | February 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: 1. Diagnosis of AML (de novo, secondary, or hematological disorder), according to WHO criteria. 2. Older than or equal to 60 years 3. ECOG performance status 0-2 4. At least one of the following factors: - Older than or equal to 70 years - Prior hematological disorder (AHD) - ECOG performance status 2 - Unfavorable karyotype (ie, adverse) defined as any cytogenetic profile except the presence of any of the following: t(8;21)(q22;q22) inv(16)(p13q22) or t(16;16)(p13;q22) t(15;17)(q22;q12) and variants 5. Provide written informed consent form. 6. Being able to comply with study procedures and follow-up evaluations. 7. Not to be fertile or willing to use a method of birth control during the study until the end of the last visit of the treatment. 8. Adequate renal and hepatic function as follows: - Total bilirubin <= 1,5 x upper of institutional normal limit (ULN) and - AST y ALT <=2,5 x ULN and - Serum creatinine <=1,0 mg/dL of serum creatinine <01,0 mg/dL, then, glomerular filtration rate (GFR) estimated must be >60 mL/min/1,73 m2 calculated from the equation of the Modification of Diet in Renal Disease (MDRD). 9. Adequate cardiac function determined by at least one of the following: - Left ventricular ejection fraction (LVEF) >=40% measured by echocardiography in Multiple Gated Acquisition (MUGA) scan or isotope angiography or - Left ventricular fractional shortening >=22% measured by echocardiography. Exclusion Criteria: 1. Diagnosis of acute promyelocytic leukaemia (APL) in French-American-British classification M3º or attending to the WHO classification t(15;17)(q22;q12), (PML/RAR and variants). 2. Pre-treatment with clofarabine. 3. Previous treatment for AML or a hematological disorder AHD (excluding palliative care, hydroxyurea, hematopoietic cytokines or lenalidomide [the latter only for a specific AHD]). Hematopoietic cytokines and lenalidomide should not have been administered within the 14 days preceding the first dose of study drug. If it is received any previous treatment for AML or AHD within the time limits allowed, drug-related toxicity, must have recovered to Grade 1 or less before the first dose of study drug. 4. Previous hematopoietic stem cell transplantation (HSCT). 5. External beam pelvic radiotherapy. 6. Have received an investigational product within 30 days before the first dose of study drug. If the patient has received any investigational product before this time, the drug-related toxicity, must have recovered to Grade 1 or less before the first dose of study drug. 7. Inadequate renal and hepatic function as follows: - Total bilirubin >1,5 x institutional upper limit normal (ULN) provided it is not attributable to the very LMA or - AST y ALT >2,5 x ULN provided it is not attributable to the very LMA or - Serum creatinine >1,0 mg/dL provided that the glomerular filtration rate (GFR) estimated to be =60 mL/min/1,73 m2 calculated by the equation of the Modification of Diet in Renal Disease (MDRD). 8. Inadequate cardiac function determined by at least one of the following: - Left ventricular ejection fraction <40% measured by echocardiography in Multiple Gated Acquisition (MUGA) or isotope angiography; or - Left ventricular fractional shortening <22% measured by echocardiography. 9. Poor general condition ECOG 3-4. 10. Refusal to sign informed consent form. 11. Inability to comply with study visits and inspections. 12. Psychiatric disorders that could interfere with the consent, participation or monitoring of the study. 13. Fungal Systemic disease, bacterial, viral or other uncontrolled infection (defined as manifestation of signs / symptoms related to ongoing infection and without improvement, although receiving adequate antibiotic therapy or other treatment). 14. Any other concomitant serious disease or a history of severe organ dysfunction or heart, kidney, liver or other organ system which may involve the patient in excessive risk when exposed to clofarabine. 15. Diagnosis of another malignancy neoplasia, unless the patient has been disease-free for at least five years after completing an attempt curative therapy with the following exceptions: - Patients with non-melanoma skin cancer, carcinoma in situ or cervical intraepithelial neoplasia, irrespective of the duration of disease-free period, are eligible for the study if it has finalized a definitive treatment for the disease. - Patients with prostate cancer confined to the organ without evidence of recurrent or progressive disease based on figures for the prostate specific antigen (PSA) are also candidates for the study if hormonal therapy has been initiated or has made a radical prostatectomy. 16. Clinical evidence which may indicate central nervous system (CNS) leukemia unless lumbar puncture to confirm the absence of leukemic blasts in the cerebrospinal fluid (CSF). 17. Previous positive test for human immunodeficiency virus (HIV). |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital General de Alicante. | Alicante | |
Spain | Hospital de la Santa Creu i Sant Pau. | Barcelona | |
Spain | Hospital Durán i Reynals (Bellvitge). | Barcelona | |
Spain | Hospital Vall d' Hebron | Barcelona | |
Spain | ICO Hospital Germans Trias I Pujol. | Barcelona | |
Spain | Hospital Reina Sofía. | Córdoba | |
Spain | Hospital Juan Canalejo. | La Coruña | |
Spain | Hospital 12 de Octubre. | Madrid | |
Spain | Hospital Ramón y Cajal. | Madrid | |
Spain | Hospital San Pedro de Alcántara. | Málaga | |
Spain | Hospital Central de Asturias. | Oviedo | |
Spain | Hospital Clínico Universitario de Salamanca. | Salamanca | |
Spain | Hospital Virgen del Rocío | Sevilla | |
Spain | Hospital Clínico de Valencia. | Valencia | |
Spain | Hospital Universitario La Fe. | Valencia |
Lead Sponsor | Collaborator |
---|---|
PETHEMA Foundation | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy | Evaluate the efficacy in terms of complete responses of induction therapy and first-line consolidation of Clofarabine and low-dose Cytarabine with AML patients aged 60 years or more. The first efficacy objective is evaluate the overall remission rate (TRG), where general reference (RG) is defined as a patient who achieved complete remission (CR) or complete remission with inadequate platelet recovery (CPR). | 1 year | No |
Secondary | To evaluate disease-free survival (DFS) | No | ||
Secondary | Evaluate the overall survival (OS) | No | ||
Secondary | To evaluate the safety | Yes | ||
Secondary | To assess the rate of mortality at 30 days | No | ||
Secondary | • The incidence, intensity (according to the latest version of the CTCAE classification), duration, causality, severity and type of AE | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01200355 -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01681537 -
Lenalidomide Plus Chemotherapy for AML
|
Phase 1 | |
Completed |
NCT01385423 -
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00995332 -
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
|
Phase 1/Phase 2 | |
Completed |
NCT00981240 -
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
Completed |
NCT00378534 -
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
|
Phase 2 | |
Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT00789256 -
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
|
N/A | |
Completed |
NCT00098033 -
Investigation of Clofarabine in Acute Leukemias
|
Phase 2 | |
Completed |
NCT01020539 -
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT04709458 -
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
|
Phase 1 | |
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Terminated |
NCT02203773 -
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT04023071 -
FT516 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 |